All In Biotech

Drug Trial Radar · NCT01131182

Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)

An Open-Label, Randomized Naturalistic Study to Evaluate the Incidence of Hypoglycemia Comparing Sitagliptin With Sulfonylurea Treatment in Patients With Type 2 Diabetes During Ramadan Fasting

Last checked: Nov 20, 2026Latest source record: Sep 21, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,147 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,147

Actual

Start

Jun 13, 2010

Primary completion

Nov 4, 2010

Study completion Nov 4, 2010

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
May 26, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will examine whether the incidence of hypoglycemia in patients fasting for Ramadan is lower when treated with sitagliptin as compared to sulfonylurea treatment.

Conditions

  • Type 2 Diabetes Mellitus (T2DM)

Interventions

  • Sitagliptin phosphateDrug

    Sitagliptin 100 mg tablet administered orally once daily over the Ramadan period.

  • Comparator: SulfonylureaDrug

    Sulfonylurea (glibenclamide, glimepiride, or gliclazide) administered orally daily over the Ramadan period as per physician's prescription

  • MetforminDrug

    Participants could continue pre-study metformin as concomitant therapy during the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants With at Least One Symptomatic Hypoglycemic EventTime frame: 30 days: first day of Ramadan (August 11) to last day of Ramadan (September 10)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.